Clinical Trial

Improved Hemodynamic Tolerance of Intermittent Hemodialysis Sessions in Intensive Care Unite Using Citrate- vs Acetate-based Dialysate

Study acronym: HEMODIACIDE
Recruiting
View on ClinicalTrials.gov →
Summary
During intermittent hemodialysis (IHD), the occurrence of intradialytic hemodynamic instability (IHI) is frequent in ICU and impacted morbidity and mortality. Bicarbonate dialysate buffer improves hemodynamic tolerance compared to acetate dialysate buffer. However, bicarbonate dialysate buffer still contains a lower concentration of acetate, which could contribute to hemodynamic instability. Recently, citrate-based dialysate in bicarbonate hemodialysis instead of acetate have been proposed. They have the appropriate authorizations for routine use. The aim of this study is to compare acetate- vs citrate-based dialysate in terms of hemodynamic tolerance and effectiveness.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-06-29; most recent amendment 2026-05-05.
Status change: Not Yet Recruiting → Recruiting 2023-12-11
Trial Details
NCT Number NCT05936710
Lead Sponsor Centre Hospitalier de Bethune
Collaborators: CHU de Lille
Conditions Intradialytic Hypotension
Enrollment 48 participants
Start Date 2023-12-07
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-08